X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (979) 979
Book Review (347) 347
Publication (48) 48
Conference Proceeding (12) 12
Book Chapter (7) 7
Magazine Article (6) 6
Book / eBook (3) 3
Newspaper Article (3) 3
Data Set (1) 1
Government Document (1) 1
Newsletter (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (710) 710
index medicus (698) 698
biosimilar pharmaceuticals - therapeutic use (370) 370
biosimilar pharmaceuticals - adverse effects (281) 281
biosimilars (278) 278
biosimilar (277) 277
pharmacology & pharmacy (254) 254
biological products (231) 231
safety (219) 219
female (204) 204
male (194) 194
oncology (186) 186
adult (179) 179
middle aged (161) 161
biosimilar pharmaceuticals (155) 155
immunogenicity (146) 146
treatment outcome (146) 146
double-blind (138) 138
efficacy (132) 132
biosimilar pharmaceuticals - administration & dosage (131) 131
infliximab (125) 125
drug approval (122) 122
animals (119) 119
therapeutic equivalency (118) 118
rheumatology (116) 116
medicine & public health (105) 105
united states (100) 100
antibodies (98) 98
biosimilar pharmaceuticals - pharmacokinetics (97) 97
clinical trials (94) 94
analysis (93) 93
monoclonal antibodies (93) 93
pharmaceutical industry (93) 93
aged (92) 92
antibodies, monoclonal - therapeutic use (90) 90
patients (88) 88
pharmacokinetics (87) 87
biosimilar pharmaceuticals - economics (84) 84
medicine, research & experimental (84) 84
rheumatoid arthritis (84) 84
fda approval (82) 82
europe (81) 81
innovator infliximab (81) 81
pharmacology (81) 81
drugs (79) 79
parallel-group (78) 78
chemotherapy (76) 76
young adult (76) 76
biosimilar pharmaceuticals - pharmacology (75) 75
pharmacovigilance (75) 75
ct-p13 (74) 74
biotechnology & applied microbiology (73) 73
studies (73) 73
cancer (72) 72
care and treatment (70) 70
immunology (70) 70
generic drugs (69) 69
review (68) 68
arthritis (66) 66
research (66) 66
antirheumatic agents - therapeutic use (65) 65
rheumatoid-arthritis (64) 64
double-blind method (63) 63
arthritis, rheumatoid - drug therapy (62) 62
drug therapy (62) 62
infliximab - therapeutic use (62) 62
proteins (62) 62
biotechnology (61) 61
usage (61) 61
biologics (59) 59
biomedicine (59) 59
internal medicine (58) 58
biopharmaceuticals (57) 57
manufacturing (57) 57
medicine (57) 57
therapy (57) 57
filgrastim (56) 56
hematology (56) 56
biological products - therapeutic use (55) 55
cancer research (54) 54
colony-stimulating factor (54) 54
interchangeability (54) 54
pharmacotherapy (53) 53
european union (52) 52
anemia (50) 50
biosimilar pharmaceuticals - standards (50) 50
pharmacology/toxicology (50) 50
comparability (49) 49
inflammatory bowel disease (49) 49
adolescent (48) 48
inflammatory bowel diseases - drug therapy (48) 48
medicine, general & internal (48) 48
neoplasms - drug therapy (48) 48
antirheumatic agents - adverse effects (47) 47
red-cell aplasia (47) 47
tumor necrosis factor-alpha - antagonists & inhibitors (47) 47
drug substitution (46) 46
extrapolation (46) 46
united states food and drug administration (46) 46
dosage and administration (45) 45
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (973) 973
German (13) 13
French (6) 6
Spanish (4) 4
Italian (2) 2
Russian (2) 2
Dutch (1) 1
Icelandic (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 1, pp. 37 - 47
IMPORTANCE: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2... 
ADJUVANT CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | THERAPY | DOCETAXEL | PLUS | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Breast Neoplasms - chemistry | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Biosimilar Pharmaceuticals - therapeutic use | Trastuzumab - therapeutic use | Double-Blind Method | Antineoplastic Agents - immunology | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Remission Induction | Disease Progression | Biosimilar Pharmaceuticals - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Survival Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 | Therapeutic Equipoise | Trastuzumab - immunology | Outcome and process assessment (Health Care) | Care and treatment | Breast cancer | Health aspects | Analysis | Young women | Patient safety | Oncology | Biological products | Biomedical research | Womens health | Index Medicus | Abridged Index Medicus
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 51 - 57
Journal Article
Arthritis Research and Therapy, ISSN 1478-6354, 01/2016, Volume 18, Issue 1, pp. 25 - 25
Background: CT-P13 (Remsima (R), Inflectra (R)) is a biosimilar of the infliximab reference product (RP; Remicade (R)) and is approved in Europe and elsewhere,... 
Immunogenicity | Infliximab | Clinical trial | Efficacy | ASAS | Safety | CT-P13 | Pharmacokinetics | Ankylosing spondylitis | Biosimilar | MULTICENTER | INNOVATOR INFLIXIMAB | ACTIVE RHEUMATOID-ARTHRITIS | METHOTREXATE | MONOCLONAL-ANTIBODY | RHEUMATOLOGY | 2010 UPDATE | SPONDYLOARTHRITIS | RECOMMENDATIONS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Infliximab - therapeutic use | Infliximab - pharmacokinetics | Young Adult | Infliximab - adverse effects | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Neutropenia - chemically induced | Antirheumatic Agents - therapeutic use | Biosimilar Pharmaceuticals - therapeutic use | Double-Blind Method | Spondylitis, Ankylosing - drug therapy | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Spondylitis, Ankylosing - metabolism | Biosimilar Pharmaceuticals - adverse effects | Self Report - standards | Spondylitis, Ankylosing - diagnosis | Internationality | Adolescent | Antirheumatic Agents - pharmacokinetics | Aged | Chemical and Drug Induced Liver Injury | Longitudinal Studies | Complications and side effects | Usage | Patient outcomes | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Methods | Index Medicus
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 58 - 64
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 10, pp. 968 - 974
Journal Article
Digestive Diseases and Sciences, ISSN 0163-2116, 11/2017, Volume 62, Issue 11, pp. 3117 - 3122
Limited data are available on long-term clinical outcomes regarding the switch from Remicade® to the infliximab biosimilar CT-P13 in inflammatory bowel disease... 
Biochemistry, general | Inflammatory bowel diseases | Disease activity | Medicine & Public Health | Infliximab | Switch | Immunogenicity | Hepatology | Gastroenterology | Biosimilar pharmaceuticals | Oncology | Transplant Surgery | ANTIBODIES | TRIAL | SINGLE-CENTER COHORT | CROHNS-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | ORIGINATOR | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Male | Colitis, Ulcerative - immunology | Infliximab - administration & dosage | Feasibility Studies | Young Adult | Infliximab - adverse effects | Netherlands | Crohn Disease - diagnosis | Tumor Necrosis Factor-alpha - immunology | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Colitis, Ulcerative - drug therapy | Gastrointestinal Agents - pharmacokinetics | Biosimilar Pharmaceuticals - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Crohn Disease - immunology | Biosimilar Pharmaceuticals - adverse effects | Colitis, Ulcerative - diagnosis | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Adolescent | Aged | Gastrointestinal Agents - adverse effects | Drug Substitution | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Therapeutic Equivalency | Index Medicus | Abridged Index Medicus | Original
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1679 - 1687
Journal Article
Journal Article